Mogylnytska L. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Aim of this study was to determinate serum level of VEGF in hypertensive patients whit type 2 diabetes, in obese hypertensive patients and in non-obese hypertensive patients. To determine relation between traditional risk factors of cardio vascular disease. Object and methods. We examined 41 hypertensive patient with type 2 diabetes (age 53,56±7,14 years, Hb1Ac 9,97±2,02%, BMI 32,28±7,4 kg/m2), 18 obese hypertensive patients (age 50,5±4,92 years, BMI 37,14±3,33 kg/m2), 10 non-obese hypertensive patients (age 52,77±6,3 years, BMI 23,35±1,59 kg/m2), 18 healthy control subjects (age 24,71±4,88 years, Hb1Ac 5,26±0,42%, BMI 24,71±4,88 kg/m2). Serum levels of VEGF were determined by immunoenzyme assay. The data were presented as means ± m. Statistical analysis was performed using the Mann- Whitney U-test, Person rank correlation coefficient, multiple regression analysis. Results. We found an increased serum level of VEGF in hypertensive patients with type 2 diabetes compared to controls (60,26±1,72 and 25,08±0,63 ng/ml respectively, р<0,01). VEGF was elevated in hypertensive patients with obesity compared to controls (44,46±2,09 and 25,08±0,63 ng/ml respectively, р<0,01) and in non-obese hypertensive patients compared to controls (31,53±0,6 and 25,08±0,63 ng/ml respectively, р<0,01). Also, we revealed raise of VEGF in hypertensive patients with type 2 diabetes compared to hypertensive patients with obesity (60,26±1,72 and 44,46±2,09 ng/ml respectively, р<0,05). There were correlation between serum level of VEGF and HbA1c (r=0,77, p<0,05), blood glucose (r=0,67, p<0,05), serum insulin levels (r=0,78, p<0,05), HOMA (r=0,82, p<0,05), BMI (r=0,38, p<0,05), LDL (r=0,55, p<0,05), HDL (r=-0,64, p<0,05), total cholesterol (r=0,59, p<0,05), triglycerides (r=0,54, p<0,05) in general group of hypertensive patients (р<0,01). Conclusion. Arterial hypertension is accompanied by an increase of serum level of VEGF in combination with type 2 diabetes, obesity, normal body mass. The revealed changes could reflect an endothelial dysfunction mostly pronounced in hypertension patients with type 2 diabetes mellitus. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of VEGF.

VEGF, endothelial dysfunction, arterial hypertension, type 2 diabetes, obesity

• Basha B. Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress? / B. Basha, S.M. Samuel, C.R. Triggle, H. Ding // Exp. Diabetes Res. – 2012. – № 2012. – Р. 481840.
• Cockcroft J. Vascular aging: shifting the paradigm of risk assessment and reduction in hypertension / J. Cockcroft, G. Mancia // J Hypertens. – 2012. – № 30. – Р. 1-2.
• ErŽen B. Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden / В. ErŽen, М. Šilar, М. Šabovič // BMC Cardiovasc Disord. – 2014. – № 14. – Р. 166.
• ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension // J Hypertens. – 2013. – № 31 (10). – Р. 1925-1938.
• Hadi A.R. Endothelial dysfunction in diabetes mellitus / A.R. Hadi, J. Suwaidi // Vasc. Health. Risk. Manag. – 2007. – № 3 (6). – Р. 853-876.
• Jansson P.A. Endothelial dysfunction in insulin resistance and type 2 diabetes / P.A. Jansson // J Intern. Med. – 2007. – № 262 (2). – Р. 173-183.
• Kubisz P. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus / Р. Kubisz, Р. Chudý, J. Stasko [et al.] // Acta Diabetol. – 2010. – № 47 (2). – Р. 119-124.
• Lim H.S. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/ dysfunction and atherosclerosis / H.S. Lim, G.Y. Lip, A.D. Blann // Atherosclerosis. – 2005. – № 180 (1). – Р. 113-118.
• Lim H.S. The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease / H.S. Lim, A.Y. Chong, B. Freestone [et al.] // Diabet. Med. – 2005. – № 22 (3). – Р. 249-255.
• Mahdy R.A. The role of vascular endothelial growth factor in the progression of diabetic vascular complications / R.A. Mahdy, W.M. Nada, K.M. Hadhoud, S.A. El-Tarhony // Eye (Lond). – 2010. – № 24 (10). – Р. 1576-1584.
• Rask-Madsen C. Vascular complications of diabetes: mechanisms of injury and protective factors / C. Rask-Madsen, G.L. King // Cell Metab. – 2013. – № 17 (1). – Р. 20-33.
• Ruszkowska-Ciastek B. A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus / B. Ruszkowska-Ciastek, A. Sokup, M.W. Socha [et al.] // J Zhejiang Univ Sci B. – 2014. – № 15 (6). – Р. 575-581.
• Thorand B. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population / В. Thorand, J. Baumert, L. Chambless [et al.] // Thromb. Vasc. Biol. – 2006. – № 26 (2). – Р. 398-405.
• Wada H. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects / Н. Wada, S. Ura, S. Kitaoka [et al.] // PLoS ONE. – 2011. – № 6 (12). – Р. 29351.
• Zakareia F.A. Correlation of peripheral arterial blood flow with plasma chemerin and VEGF in diabetic peripheral vascular disease / F.A. Zakareia // Biomarkers Med. – 2012. – № 6. – Р. 81-87.

«Bulletin of problems biology and medicine» Issue 4 Part 3 (141), 2017 year, 158-163 pages, index UDK 616–092

10.29254/2077–4214–2017–4–3–141–158-163